Actein, a cycloartane triterpene glycoside extracted from the rhizomes of Cimicifuga foetida L. was documented as a selective cell growth inhibitor of breast cancer cells as well as able to act in a synergic manner with consecrated chemotherapy agents; Yue et al. investigated in 2016 the activity of actein on tumor angiogenesis, an essential step in tumor development and metastasis; in vitro results showed that actein suppressed the expression of VEGFR1, pJNK, and pERK subsequently inhibiting cell proliferation, migration and motility. The gene discussed is EIF2AK3; the disease is neoplasm.